Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.
Hematol Oncol Clin North Am
; 37(6): 1169-1188, 2023 12.
Article
em En
| MEDLINE
| ID: mdl-37349152
ABSTRACT
As chimeric antigen receptor (CAR) T-cell therapy is increasingly integrated into clinical practice across a range of malignancies, identifying and treating inflammatory toxicities will be vital to success. Early experiences with CD19-targeted CAR T-cell therapy identified cytokine release syndrome and neurotoxicity as key acute toxicities and led to unified initiatives to mitigate the influence of these complications. In this section, we provide an update on the current state of CAR T-cell-related toxicities, with an emphasis on emerging acute toxicities affecting additional organ systems and considerations for delayed toxicities and late effects.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos Quiméricos
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Hematol Oncol Clin North Am
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos